Hot Products
| Catalog No. | Information |
| CFN92548 | Alisol G Alisol G has hCE2 inhibitory effects. |
| CFN92404 | Alisol O Standard reference |
| CFN92568 | Alizarin Alizarin has a selective and effective inhibitory activity towards cancerous cells, it acts through the inhibition of ERK phosphorylation and cell cycle arrest in the S-phase. Alizarin has antigenotoxic activity, which can be explained by inhibition of CYP activities responsible for activating the mutagens. |
| CFN92569 | Alizarin 2-methyl ether Alizarin 2-methyl ether enhances adipocyte differentiation by up to 131%, it could be beneficial in the treatment of diabetes. |
| CFN97557 | Allantoin Allantoin, as I-1R agonist, has the potential to develop as a new therapeutic agent for hypertension. Allantoin has memory-enhancing, anti-oxidative and anti-inflammatory activities; it can enhance the antifungal activity of Nanoencapsulation. Allantoin is a skin conditioning agent that promotes healthy skin, stimulates new and healthy tissue growth. Allantoin mediates PI3K-Akt-GSK-3β signal pathway. |
| CFN90201 | Allicin Allicin exerts antioxidant, bactericidal, anti-cancer, anti-inflammatory activities, it exerts an inhibitory immunomodulatory effect on intestinal epithelial cells. Allicin could significantly inhibit vascular smooth muscle cells' proliferation and migration induced by insulin, which may be related to the inhibition of the activation of ERK signal path. Allicin is beneficial in reducing blood cholesterol, triglycerides levels and systolic blood pressure in hypercholesterolemic rats, it may beneficially affect two risk factors for atherosclerosis–hyperlipidemia and hypertension. |
| CFN93533 | Alliin Alliin has antiglycating potential , it offers protection against glucose or methyglyoxal induced glycation of superoxide dismutase, hence is expected to have therapeutic potential in the prevention of glycation-mediated diabetic complications. Alliin has anti-inflammatory activity, it protects against Lipopolysaccharides (LPS)-induced acute lung injury (ALI) by activating PPARγ, which subsequently inhibits LPS-induced NF-κB activation and inflammatory response; alliin has an inhibitory effect in osteoclasteogenesis with a dose-dependent manner via blocking the c-Fos-NFATc1 signaling pathway, it could be a potential therapeutic agent in the treatment of osteoporosis. Alliin and sabinene have detectable levels of antimicrobial activity. |
| CFN91880 | Alloalantolactone Alloalantolactone shows activity against M. tuberculosis (32 micrograms/ml). |
| CFN98254 | Allocryptopine Allocryptopine has certain effects on anti-injury for hepatocyte, ameliorating liver function, and prohibiting hepatic fibrosis; it increases mRNA levels of cytochromes P450 1A in human hepatocytes and HepG2 cells independently of AhR. Allocryptopine induces a relaxing effect on the ileum by inhibiting phosphodiesterase enzyme, and thus elevating cellular cAMP and its contractile effect on the urinary bladder by affecting alpha-adrenergic receptors in this tissue, it can block human ether-a-go-go related gene (hERG) potassium channels expressed in HEK293 cells. |
| CFN93037 | Alloimperatorin Alloimperatorin exhibits in vitro antitumor activity in HL-60 acute myeloid leukemia cancer cells via inducing apoptosis, cell cycle disruption and inhibition of cell migration. It photosensitizes efficiently the hemolysis of erythrocytes. |
